Q-omics provides the consensus-scored DDC profile across patient tissues and cancer cell-line models. DDC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DDC is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, DDC RNA expression shows 14,957 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where DDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDC survival associations across molecular data types. DDC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDC RNA expression–survival associations across cancer types. High DDC expression shows unfavorable associations in UCEC, STAD, BRCA and ESCA, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DDC RNA expression.
This table summarizes DDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDC shows lower tumor expression in KICH, KIRP, THCA, LUAD and LUSC and higher tumor expression in HNSC. The KICH box plot shows higher DDC RNA expression in normal versus tumor tissue (log2 FC = −5.835, t-test p < 0.001).
This table shows molecular features associated with DDC in patient tissues and cancer cell lines. In patient samples, DDC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
